<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10766">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02966795</url>
  </required_header>
  <id_info>
    <org_study_id>M16-126</org_study_id>
    <secondary_id>2016-003192-22</secondary_id>
    <nct_id>NCT02966795</nct_id>
  </id_info>
  <brief_title>A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection</brief_title>
  <official_title>M16-126 A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 3b, open-label, multicenter study to evaluate the efficacy and safety of glecaprevir
      (ABT-493)/pibrentasvir (ABT-530) for an 8- or 12-week treatment duration in participants
      with chronic Hepatitis C Virus (HCV) genotype (GT) 5 or 6 infection, with or without
      compensated cirrhosis, who are either HCV treatment-naïve or treatment experienced with
      interferon (IFN) or pegylated interferon (pegIFN) with or without ribavirin (RBV) (defined
      as P/R treatment-experienced) or sofosbuvir (SOF) plus RBV with or without pegIFN (defined
      as SOF plus RBV treatment-experienced).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with sustained virologic response 12 weeks post dosing (SVR12) within each genotype (GT; GT5 and GT6) separately across treatment arms</measure>
    <time_frame>12 weeks after last dose of study drug</time_frame>
    <description>SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) levels less than the lower limit of quantitation (LLOQ) (less than 15 IU/mL) 12 weeks after the last actual dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with on-treatment HCV virologic failure</measure>
    <time_frame>During treatment (up to 8 or 12 weeks, treatment arm specific) and at the end of treatment with at least 6 weeks of treatment.</time_frame>
    <description>HCV virologic failure defined as:
Confirmed increase from nadir in HCV RNA (defined as 2 consecutive HCV RNA measurement of greater than 1 log10 IU/mL above nadir) at any time point during study drug treatment; or
Confirmed HCV RNA greater than or equal to 100 IU/mL (defined as 2 consecutive HCV RNA measurements greater than or equal to 100 IU/mL) after HCV RNA less than LLOQ during study drug treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with post-treatment HCV virologic relapse</measure>
    <time_frame>At the end of treatment (8 or 12 weeks, treatment arm specific) and 12 weeks after last dose of treatment.</time_frame>
    <description>Post-treatment virologic failure (Relapse) is defined as:
- Confirmed HCV RNA ≥ LLOQ (defined as 2 consecutive HCV RNA measurements ≥ LLOQ) between end of treatment and 12 weeks after the last dose of study drug (up to and including the SVR12 assessment time point), for subjects who completed treatment (defined as study drug duration ≥ 77 days and ≥ 105 days for subjects allocated to the 12 and 16 week durations, respectively) and had HCV RNA &lt; LLOQ at final treatment visit, excluding reinfection, as described below.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection</condition>
  <arm_group>
    <arm_group_label>ARM A: GLE/PIB for 8 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A: Hepatitis C virus genotype 5 or 6 (HCV GT 5 or 6) non-cirrhotic participants treated with Glecaprevir (GLE)/Pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: GLE/PIB for 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B: HCV GT 5 or 6 participants with compensated cirrhosis treated with GLE/PIB 300 mg/120 mg QD for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glecaprevir/Pibrentasvir</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>ARM A: GLE/PIB for 8 weeks</arm_group_label>
    <arm_group_label>Arm B: GLE/PIB for 12 weeks</arm_group_label>
    <other_name>ABT-493/ABT-530</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Screening laboratory result indicating hepatitis C virus (HCV) GT5 or 6 infection.

          -  Participant has a positive anti-HCV antibody (Ab) and plasma HCV ribonucleic acid
             (RNA) greater than or equal to 1000 IU/mL at Screening Visit.

          -  Participant must be HCV treatment-naïve (i.e., has never received a single dose of
             any approved or investigational anti-HCV medication) or treatment-experienced (i.e.,
             has failed prior interferon [IFN] or pegylated interferon [pegIFN] with or without
             ribavirin [RBV], or sofosbuvir [SOF] plus RBV with or without pegIFN therapy). Prior
             HCV treatment with any other approved or investigational medications is not allowed.
             Previous HCV treatment must have been completed greater than or equal to 2 months
             prior to screening.

          -  Participant must be documented as having no cirrhosis or compensated cirrhosis.

        Exclusion Criteria:

          -  Female participant who is pregnant, breastfeeding, or is considering becoming
             pregnant during the study or for approximately 30 days after the last dose of study
             drug.

          -  Recent (within 6 months prior to study drug administration) history of drug or
             alcohol abuse that could preclude adherence to the protocol in the opinion of the
             investigator.

          -  Positive test result at screening for hepatitis B surface antigen (HBsAg) or
             anti-human immunodeficiency virus antibody (HIV Ab).

          -  HCV genotype performed during screening indicating co-infection with more than one
             HCV genotype.

          -  History of severe, life-threatening or other significant sensitivity to any
             excipients of the study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katia Alves, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie LC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kerstin Krauss, BS</last_name>
    <phone>+49 621 589 1857</phone>
    <email>kerstin.krauss@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christina Giannoulis, BA</last_name>
    <phone>+1 847 938 2882</phone>
    <email>christina.giannoulis@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 157045</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 157045, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 157042</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 157042, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 157027</name>
      <address>
        <city>Kingswood</city>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 157027, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 157030</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 157030, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 157031</name>
      <address>
        <city>Calgary</city>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 157031, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 157034</name>
      <address>
        <city>CLERMONT-FERRAND Cedex 1</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 157034, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 157028</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 157028, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 157036</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 157036, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 157035</name>
      <address>
        <city>PESSAC Cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 157035, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 156855</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 156855, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 157037</name>
      <address>
        <city>Singapore</city>
        <zip>169856</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 157037, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 157039</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 157039, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 2, 2017</lastchanged_date>
  <firstreceived_date>November 15, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sofosbuvir (SOF)</keyword>
  <keyword>ribavirin (RBV)</keyword>
  <keyword>pegylated interferon (pegIFN)</keyword>
  <keyword>interferon (IFN)</keyword>
  <keyword>pegylated-interferon (pegIFN)</keyword>
  <keyword>non-cirrhotic</keyword>
  <keyword>glecaprevir</keyword>
  <keyword>compensated cirrhosis</keyword>
  <keyword>pibrentasvir</keyword>
  <keyword>Sustained Virologic Response 12 weeks post dosing (SVR12)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
